| Dr Ajala Osagie Ngarndi, MD | |
|
1133 Eagles Landing Pkwy, Stockbridge, GA 30281 | |
| (678) 604-1000 | |
| Not Available |
| Full Name | Dr Ajala Osagie Ngarndi |
|---|---|
| Gender | Female |
| Speciality | Emergency Medicine |
| Experience | 11 Years |
| Location | 1133 Eagles Landing Pkwy, Stockbridge, Georgia |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1215377726 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 078112 (Georgia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Piedmont Fayette Hospital | Fayetteville, GA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Atlantic Cod Emergency Physicians Llc | 0345567616 | 17 |
News Archive
Medtronic, today announced that the U.S. Food and Drug Administration approved its Revo MRI SureScan pacing system, the first and only pacemaker in the U.S. specifically designed for use in an Magnetic Resonance Imaging environment and approved as MR-Conditional. Shipments of Revo MRI will begin immediately.
WEHI researchers have identified a key molecular regulator involved in the progression and spread of stomach cancer, suggesting a potential new approach to treat this devastating disease.
Gilead Sciences, Inc. "will donate 445,000 vials of AmBisome over five years to help the World Health Organization (WHO) treat more than 50,000 patients with visceral leishmaniasis (VL), also known as kala-azar," a Gilead press release states, adding, "If sold at Gilead's no-profit access price, today's donation would cost more than $8 million."
The study by consulting firm Avalere Health concludes that less than a third of the 6.3 million who have signed up for Medicaid have done so because of the health law's expansion of eligibility. Developments in Virginia and Florida are also covered.
Using blood, urine and tissue analysis of a unique mouse model, a team led by UC Davis researchers has identified several proteins as diagnostic biomarkers and potential therapeutic targets for kidney cancer. Subject to follow-up validation testing, inhibition of these proteins and several related pathways holds promise as a form of therapy to slow the growth of kidney tumors.
› Verified 7 days ago
| Entity Name | Inphynet Primary Care Physicians Southeast Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770521460 PECOS PAC ID: 3779497045 Enrollment ID: O20031119000600 |
News Archive
Medtronic, today announced that the U.S. Food and Drug Administration approved its Revo MRI SureScan pacing system, the first and only pacemaker in the U.S. specifically designed for use in an Magnetic Resonance Imaging environment and approved as MR-Conditional. Shipments of Revo MRI will begin immediately.
WEHI researchers have identified a key molecular regulator involved in the progression and spread of stomach cancer, suggesting a potential new approach to treat this devastating disease.
Gilead Sciences, Inc. "will donate 445,000 vials of AmBisome over five years to help the World Health Organization (WHO) treat more than 50,000 patients with visceral leishmaniasis (VL), also known as kala-azar," a Gilead press release states, adding, "If sold at Gilead's no-profit access price, today's donation would cost more than $8 million."
The study by consulting firm Avalere Health concludes that less than a third of the 6.3 million who have signed up for Medicaid have done so because of the health law's expansion of eligibility. Developments in Virginia and Florida are also covered.
Using blood, urine and tissue analysis of a unique mouse model, a team led by UC Davis researchers has identified several proteins as diagnostic biomarkers and potential therapeutic targets for kidney cancer. Subject to follow-up validation testing, inhibition of these proteins and several related pathways holds promise as a form of therapy to slow the growth of kidney tumors.
› Verified 7 days ago
| Entity Name | Emerginet, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1164480869 PECOS PAC ID: 4082515853 Enrollment ID: O20040115000322 |
News Archive
Medtronic, today announced that the U.S. Food and Drug Administration approved its Revo MRI SureScan pacing system, the first and only pacemaker in the U.S. specifically designed for use in an Magnetic Resonance Imaging environment and approved as MR-Conditional. Shipments of Revo MRI will begin immediately.
WEHI researchers have identified a key molecular regulator involved in the progression and spread of stomach cancer, suggesting a potential new approach to treat this devastating disease.
Gilead Sciences, Inc. "will donate 445,000 vials of AmBisome over five years to help the World Health Organization (WHO) treat more than 50,000 patients with visceral leishmaniasis (VL), also known as kala-azar," a Gilead press release states, adding, "If sold at Gilead's no-profit access price, today's donation would cost more than $8 million."
The study by consulting firm Avalere Health concludes that less than a third of the 6.3 million who have signed up for Medicaid have done so because of the health law's expansion of eligibility. Developments in Virginia and Florida are also covered.
Using blood, urine and tissue analysis of a unique mouse model, a team led by UC Davis researchers has identified several proteins as diagnostic biomarkers and potential therapeutic targets for kidney cancer. Subject to follow-up validation testing, inhibition of these proteins and several related pathways holds promise as a form of therapy to slow the growth of kidney tumors.
› Verified 7 days ago
| Entity Name | Emerginet Henry, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1811946627 PECOS PAC ID: 4981594900 Enrollment ID: O20040316000137 |
News Archive
Medtronic, today announced that the U.S. Food and Drug Administration approved its Revo MRI SureScan pacing system, the first and only pacemaker in the U.S. specifically designed for use in an Magnetic Resonance Imaging environment and approved as MR-Conditional. Shipments of Revo MRI will begin immediately.
WEHI researchers have identified a key molecular regulator involved in the progression and spread of stomach cancer, suggesting a potential new approach to treat this devastating disease.
Gilead Sciences, Inc. "will donate 445,000 vials of AmBisome over five years to help the World Health Organization (WHO) treat more than 50,000 patients with visceral leishmaniasis (VL), also known as kala-azar," a Gilead press release states, adding, "If sold at Gilead's no-profit access price, today's donation would cost more than $8 million."
The study by consulting firm Avalere Health concludes that less than a third of the 6.3 million who have signed up for Medicaid have done so because of the health law's expansion of eligibility. Developments in Virginia and Florida are also covered.
Using blood, urine and tissue analysis of a unique mouse model, a team led by UC Davis researchers has identified several proteins as diagnostic biomarkers and potential therapeutic targets for kidney cancer. Subject to follow-up validation testing, inhibition of these proteins and several related pathways holds promise as a form of therapy to slow the growth of kidney tumors.
› Verified 7 days ago
| Entity Name | Angelfish Emergency Physicians Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407259500 PECOS PAC ID: 7517282817 Enrollment ID: O20150209000684 |
News Archive
Medtronic, today announced that the U.S. Food and Drug Administration approved its Revo MRI SureScan pacing system, the first and only pacemaker in the U.S. specifically designed for use in an Magnetic Resonance Imaging environment and approved as MR-Conditional. Shipments of Revo MRI will begin immediately.
WEHI researchers have identified a key molecular regulator involved in the progression and spread of stomach cancer, suggesting a potential new approach to treat this devastating disease.
Gilead Sciences, Inc. "will donate 445,000 vials of AmBisome over five years to help the World Health Organization (WHO) treat more than 50,000 patients with visceral leishmaniasis (VL), also known as kala-azar," a Gilead press release states, adding, "If sold at Gilead's no-profit access price, today's donation would cost more than $8 million."
The study by consulting firm Avalere Health concludes that less than a third of the 6.3 million who have signed up for Medicaid have done so because of the health law's expansion of eligibility. Developments in Virginia and Florida are also covered.
Using blood, urine and tissue analysis of a unique mouse model, a team led by UC Davis researchers has identified several proteins as diagnostic biomarkers and potential therapeutic targets for kidney cancer. Subject to follow-up validation testing, inhibition of these proteins and several related pathways holds promise as a form of therapy to slow the growth of kidney tumors.
› Verified 7 days ago
| Entity Name | Atlantic Cod Emergency Physicians Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801292693 PECOS PAC ID: 0345567616 Enrollment ID: O20150325001463 |
News Archive
Medtronic, today announced that the U.S. Food and Drug Administration approved its Revo MRI SureScan pacing system, the first and only pacemaker in the U.S. specifically designed for use in an Magnetic Resonance Imaging environment and approved as MR-Conditional. Shipments of Revo MRI will begin immediately.
WEHI researchers have identified a key molecular regulator involved in the progression and spread of stomach cancer, suggesting a potential new approach to treat this devastating disease.
Gilead Sciences, Inc. "will donate 445,000 vials of AmBisome over five years to help the World Health Organization (WHO) treat more than 50,000 patients with visceral leishmaniasis (VL), also known as kala-azar," a Gilead press release states, adding, "If sold at Gilead's no-profit access price, today's donation would cost more than $8 million."
The study by consulting firm Avalere Health concludes that less than a third of the 6.3 million who have signed up for Medicaid have done so because of the health law's expansion of eligibility. Developments in Virginia and Florida are also covered.
Using blood, urine and tissue analysis of a unique mouse model, a team led by UC Davis researchers has identified several proteins as diagnostic biomarkers and potential therapeutic targets for kidney cancer. Subject to follow-up validation testing, inhibition of these proteins and several related pathways holds promise as a form of therapy to slow the growth of kidney tumors.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Ajala Osagie Ngarndi, MD 1133 Eagles Landing Pkwy, Stockbridge, GA 30281-5085 Ph: (678) 604-1000 | Dr Ajala Osagie Ngarndi, MD 1133 Eagles Landing Pkwy, Stockbridge, GA 30281 Ph: (678) 604-1000 |
News Archive
Medtronic, today announced that the U.S. Food and Drug Administration approved its Revo MRI SureScan pacing system, the first and only pacemaker in the U.S. specifically designed for use in an Magnetic Resonance Imaging environment and approved as MR-Conditional. Shipments of Revo MRI will begin immediately.
WEHI researchers have identified a key molecular regulator involved in the progression and spread of stomach cancer, suggesting a potential new approach to treat this devastating disease.
Gilead Sciences, Inc. "will donate 445,000 vials of AmBisome over five years to help the World Health Organization (WHO) treat more than 50,000 patients with visceral leishmaniasis (VL), also known as kala-azar," a Gilead press release states, adding, "If sold at Gilead's no-profit access price, today's donation would cost more than $8 million."
The study by consulting firm Avalere Health concludes that less than a third of the 6.3 million who have signed up for Medicaid have done so because of the health law's expansion of eligibility. Developments in Virginia and Florida are also covered.
Using blood, urine and tissue analysis of a unique mouse model, a team led by UC Davis researchers has identified several proteins as diagnostic biomarkers and potential therapeutic targets for kidney cancer. Subject to follow-up validation testing, inhibition of these proteins and several related pathways holds promise as a form of therapy to slow the growth of kidney tumors.
› Verified 7 days ago
Dr. Terry Ky-sieu Tran, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1133 Eagles Landing Pkwy, Stockbridge, GA 30281 Phone: 678-604-1000 | |
Yaa Manu, M.D Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1133 Eagles Landing Pkwy, Stockbridge, GA 30281 Phone: 678-604-1000 | |
Okiki Louis, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 1133 Eagles Landing Pkwy, Stockbridge, GA 30281 Phone: 770-994-9326 Fax: 770-994-4747 | |
Hesiri M Fernando, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1133 Eagles Landing Pkwy, Stockbridge, GA 30281 Phone: 770-994-9326 Fax: 770-994-4747 | |
Jeffery Ray Mcgee, PA-C, AA-C Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1740 Hudson Bridge Rd, Suite 1218, Stockbridge, GA 30281 Phone: 678-604-1053 | |
Dr. Miles Anthony Medina, D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1133 Eagles Landing Pkwy # Er, Stockbridge, GA 30281 Phone: 678-604-1000 |